Global Workforce Jolt: Wegovy Maker Novo Nordisk Axes 9,000 Jobs Worldwide!
Novo Nordisk A/S, the maker of the popular weight-loss drug Wegovy, announced significant job cuts impacting 9,000 employees. This restructuring aims to streamline operations and reallocate resources amid fierce competition from rivals like Eli Lilly and compounded drugs, despite a previous hiring surge driven by the drug's success.
Novo Nordisk A/S, the Danish pharmaceutical giant renowned for its viral weight-loss drug Wegovy, has announced a significant restructuring plan involving the reduction of 9,000 jobs, representing 11 percent of its total workforce. This decision comes as the company navigates intense competition from its US rival Eli Lilly and the proliferation of compounded similar drugs in the market. Once recognized as Europe's most valuable company by market capitalization, Novo Nordisk is now strategically repositioning itself to revive growth and enhance operational efficiency.
The comprehensive restructuring is projected to yield annual savings of 8 billion Danish crowns ($1.25 billion). Novo Nordisk elaborated that these job cuts are an integral part of a